Actively Recruiting
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
Led by Emory University · Updated on 2026-02-18
50
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications. Participants will be randomly assigned to repeated red blood cell transfusions or the standard of care. Participants will be on study for about 8-10 months (Pregnancy through 2 months post-partum).
CONDITIONS
Official Title
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female
- Diagnosis of sickle cell disease of any genotype (HbSS, HbSC, HbSb2 thalassemia)
- Age 18 years or older
- Currently pregnant between 6 and 20 weeks of gestation
- Able to understand the study and give informed consent
- For those with private insurance, pre-approval for blood transfusions
You will not qualify if you...
- Currently receiving chronic transfusion therapy before pregnancy
- History of delayed hemolytic transfusion reaction (DHTR) with hyperhemolysis
- Red cell antibody history preventing adequate transfusion support
- Unable or unwilling to receive blood transfusions for social, religious, or clinical reasons
- Known current triplet pregnancy
- Major medical or psychiatric illness preventing participation as judged by clinician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Grady Health System
Atlanta, Georgia, United States, 30303
Actively Recruiting
Research Team
R
Ross Fasano, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here